+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Cellectar Biosciences Inc (CLRB) - Financial and Strategic SWOT Analysis Review

1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 4

FEATURED COMPANIES

  • Avelas Biosciences Inc
  • Exelixis Inc
  • Genentech Inc
  • MEI Pharma Inc
  • Nimbus Therapeutics LLC
  • Seattle Genetics Inc
  • MORE
Cellectar Biosciences Inc (CLRB) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by the publisher to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:
  • Business description - A detailed description of the company’s operations and business divisions.
  • Corporate strategy - Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives’ employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

Cellectar Biosciences Inc (Cellectar), is a biopharmaceutical company that discovers, develops and commercializes drugs for treatment of cancer. The company’s proprietary technology, phospholipid drug conjugates (PDC) delivery platform that develops PDCs for the treatment and diagnosis of cancer. Its lead product, CLR 131, is a small-molecule PDC, in phase II clinical trials for the treatment of relapse or refractory multiple myeloma and B-cell lymphomas. The company is also evaluating CLR 131 in Phase I clinical trials for treatment of Pediatric patients with solid tumors, lymphomas; malignant brain tumors, head and neck cancer. Cellectar’s other products in pipeline include CLR 1800, CLR 1900, CLR 2000, CLR 2100, CLR 2200 and CLR 12120 for solid tumors. The company’s seeks in collaboration with Orano Med, Onconova Therapeutics; Avicenna Oncology and University of Wisconsin. Cellectar is headquartered in Florham Park, New Jersey, the US.

Cellectar Biosciences Inc Key Recent Developments

Jul 01, 2020: Cellectar appoints Dr. John Friend as Chief Medical Officer
Jun 01, 2020: Cellectar granted SME status by the European Medicines Agency
May 07, 2020: Cellectar reports first quarter 2020 financial results and provides a corporate update
Mar 09, 2020: Cellectar reports financial results for year ended December 31, 2019 and provides a corporate update
Jan 19, 2020: Cellectar Biosciences to present at Biotech Showcase 2020

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Avelas Biosciences Inc
  • Exelixis Inc
  • Genentech Inc
  • MEI Pharma Inc
  • Nimbus Therapeutics LLC
  • Seattle Genetics Inc
  • MORE
Section 1 - About the Company
  • Cellectar Biosciences Inc - Key Facts
  • Cellectar Biosciences Inc - Key Employees
  • Cellectar Biosciences Inc - Key Employee Biographies
  • Cellectar Biosciences Inc - Major Products and Services
  • Cellectar Biosciences Inc - History
  • Cellectar Biosciences Inc - Company Statement
  • Cellectar Biosciences Inc - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
Section 2 - Company Analysis
  • Company Overview
  • Cellectar Biosciences Inc - Business Description
  • Cellectar Biosciences Inc - SWOT Analysis
  • SWOT Analysis - Overview
  • Cellectar Biosciences Inc - Strengths
  • Cellectar Biosciences Inc - Weaknesses
  • Cellectar Biosciences Inc - Opportunities
  • Cellectar Biosciences Inc - Threats
  • Cellectar Biosciences Inc - Key Competitors
Section 3 - Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts
Section 4 - Company’s Lifesciences Financial Deals and Alliances
  • Cellectar Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
  • Cellectar Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
  • Cellectar Biosciences Inc, Recent Deals Summary
Section 5 - Company’s Recent Developments
  • Jul 01, 2020: Cellectar appoints Dr. John Friend as Chief Medical Officer
  • Jun 01, 2020: Cellectar granted SME status by the European Medicines Agency
  • May 07, 2020: Cellectar reports first quarter 2020 financial results and provides a corporate update
  • Mar 09, 2020: Cellectar reports financial results for year ended December 31, 2019 and provides a corporate update
  • Jan 19, 2020: Cellectar Biosciences to present at Biotech Showcase 2020
  • Jan 07, 2020: Cellectar appoints Dr. Igor Grachev as Chief Medical Officer
  • Nov 12, 2019: Cellectar reports third quarter 2019 financial results and provides a corporate update
  • Aug 15, 2019: Cellectar appoints Dov Elefant as chief financial officer
  • Aug 14, 2019: Cellectar reports second quarter 2019 financial results and provides a corporate update
  • May 06, 2019: Cellectar Reports First Quarter 2019 Financial Results and Provides a Corporate Update
Section 6 - Appendix
  • Methodology
  • Ratio Definitions
  • About the Publisher
  • Contact
  • Disclaimer
List of Tables
  • Cellectar Biosciences Inc, Key Facts
  • Cellectar Biosciences Inc, Key Employees
  • Cellectar Biosciences Inc, Key Employee Biographies
  • Cellectar Biosciences Inc, Major Products and Services
  • Cellectar Biosciences Inc, History
  • Cellectar Biosciences Inc, Subsidiaries
  • Cellectar Biosciences Inc, Key Competitors
  • Cellectar Biosciences Inc, Ratios based on current share price
  • Cellectar Biosciences Inc, Annual Ratios
  • Cellectar Biosciences Inc, Annual Ratios (Cont...1)
  • Cellectar Biosciences Inc, Interim Ratios
  • Cellectar Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
  • Cellectar Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
  • Cellectar Biosciences Inc, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios
List of Figures
  • Cellectar Biosciences Inc, Performance Chart (2015 - 2019)
  • Cellectar Biosciences Inc, Ratio Charts
  • Cellectar Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
  • Cellectar Biosciences Inc, Pharmaceuticals & Healthcare, Deals by Type, 2014 to YTD 2020
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Seattle Genetics Inc
  • Nimbus Therapeutics LLC
  • MEI Pharma Inc
  • Infinity Pharmaceuticals Inc
  • Genentech Inc
  • Exelixis Inc
  • Avelas Biosciences Inc
Note: Product cover images may vary from those shown
Adroll
adroll